Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05364073 · ClinicalTrials.gov registry record · Phase 1
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Metastatic Non Small Cell Lung Cancer, sponsored by ArriVent BioPharma.
- Active
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT05364073: Active Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Metastatic Non Small Cell Lung Cancer, sponsored by ArriVent BioPharma.
NCT05364073 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by ArriVent BioPharma. The registered enrollment target is 160 participants, below the 282-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05364073, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by ArriVent BioPharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).
Conditions Studied
Interventions
- DRUG Furmonertinib
Study Locations (20)
California
- ArriVent Investigative Site - Sacramento
- ArriVent Investigative Site - Whittier
New South Wales
- ArriVent Investigative Site - Blacktown
- ArriVent Investigative Site - St Leonards
Other
- Arrivent Investigative Site - Edmonton
- Arrivent Investigative Site - Toronto
Beijing Municipality
- Allist Investigative Site - Beijing
- Allist Investigative Site - Chaoyang
Henan
- Allist Investigative Site - Zhengzhou
- Allist Investigative Site - Zhengzhou
Arizona
- ArriVent Investigative Site - Prescott
Florida
- ArriVent Investigative Site - Celebration
Michigan
- ArriVent Investigative Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT05364073 still lists
NCT05364073 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 282-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (43% lower).
The record links to 6 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which Furmonertinib is the first listed.
NCT05364073 names 20 study sites across 15 states, led by California, New South Wales, Other.
Frequently Asked Questions
What is clinical trial NCT05364073 about?
NCT05364073 is a clinical study titled "Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations". This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including unc...
What is the current status of trial NCT05364073?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2022-06-30. Estimated completion is 2026-12-31.
What conditions does trial NCT05364073 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Metastatic Non Small Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR Exon 20 Mutations, HER2 Exon 20 Mutations.
What interventions are being tested in trial NCT05364073?
The interventions under investigation include: Furmonertinib (DRUG).
Who is sponsoring clinical trial NCT05364073?
This trial is sponsored by ArriVent BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05364073 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05364073's enrollment target sits among peer trials
160 34th of 59 higher than 26 of 59 other Non-small Cell Lung Cancer (NSCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI